Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
EXPIRY: 06/2028
These findings are meaningful though most studies are small, follow-up periods are limited, and there is not yet sufficient evidence to recommend GLP-1 medications as a treatment for eating disorder symptoms ( Bartel et al., Int J Eating Disorders, 2024 )
First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in June 2024 were slightly lower than rates in March 2024 (6.90%)
These numbers are meaningfully higher than tirzepatide discontinuation rates and represent an important consideration for researchers planning long-term protocols
SURMOUNT-1 data showed 22.5% average body weight reduction at this dose over 72 weeks
US$ 29.78
US$ 23.19
US$ 20.94
US$ 21.91
US$ 20.78
